Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting
LONDON and PHILADELPHIA – March 26, 2025 – Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will have three presentations at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025 in Chicago, IL.
The poster presentations will feature data from the Company’s proprietary pre|CISION® platform and pipeline of next generation peptide drug conjugates (PDCs), including AVA6000, a PDC consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by FAP in the tumor microenvironment via a pharmacokinetics and clinical presentation, and preclinical pharmacology highlights for AVA6103, a PDC comprised of the pre|CISION® peptide linked to exatecan. The third presentation will describe detailed analysis of the target fibroblast activation protein-alpha (FAPα), the protease that forms the basis of the pre|CISION® platform.
Details for Avacta’s poster presentations are below and can be found on the AACR website:
Abstract Number and Title: #3139: The novel PDC AVA6103 is a FAP-enabled pre|CISION® medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavage
· Session Category: Experimental and Molecular Therapeutics
· Session Title: Therapeutic Approach to Attack the Tumor Microenvironment
· Session Date and Time: Monday, April 28, 2025, 2:00 – 5:00 p.m. CT
Abstract Number and Title: #2699: Investigating fibroblast activation protein alpha (FAPα) as a therapeutic target for delivery of pre|CISION® cancer medicines: Expression, spatial localization and functional insights
· Session Category: Tumor Biology
· Session Title: Targeting the Tumor Microenvironment: A Brave New World
· Session Date and Time: Monday, April 28, 2025, 2:00 – 5:00 p.m. CT
Abstract Number and Title: #CT15: Comparative pharmacokinetics and tumor activation of fibroblast activation protein (FAP)-enabled pre|CISION® peptide drug conjugates
· Session Title: First-in-Human Phase I Clinical Trials 2
· Session Date and Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CT
-Ends-
For further information from Avacta, please contact:
|
Avacta Group plc Michael Vinegrad, Group Communications Director |
